Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
legislation
|
| gptkbp:addresses |
public health emergencies
opioid crisis food safety issues |
| gptkbp:amends |
2022
|
| gptkbp:enactedBy |
gptkb:United_States_Congress
|
| gptkbp:encourages |
collaboration with industry
|
| gptkbp:enhances |
safety measures for drugs
FDA's_ability_to_respond_to_crises FDA's_communication_strategies FDA's_enforcement_capabilities FDA's_international_collaboration FDA's_workforce_development_programs |
| gptkbp:established |
new regulatory frameworks
|
| gptkbp:facilitates |
research collaborations
expedited review processes accelerated approval pathways |
| gptkbp:firstAwarded |
2017
|
| https://www.w3.org/2000/01/rdf-schema#label |
FDA Reauthorization Act
|
| gptkbp:impact |
gptkb:Food_and_Drug_Administration
|
| gptkbp:improves |
supply chain security
data sharing among agencies regulatory science patient access to therapies access to rare disease treatments transparency_in_FDA_processes |
| gptkbp:includes |
user fees
provisions for health equity provisions for health technology assessment provisions for antimicrobial resistance provisions for biosimilars provisions for cosmetic safety provisions for drug pricing transparency provisions for pediatric studies |
| gptkbp:mandates |
post-market surveillance
risk evaluation and mitigation strategies safety reporting for devices |
| gptkbp:promotes |
public awareness campaigns
patient-centered outcomes research generic drug competition |
| gptkbp:provides |
funding for public health initiatives
guidance for novel therapies resources for emergency preparedness. increased_funding_for_FDA_initiatives |
| gptkbp:purpose |
funding_for_FDA_programs
|
| gptkbp:regulates |
drug approval process
medical device approval process |
| gptkbp:requires |
clinical trial data transparency
reporting of drug shortages |
| gptkbp:signature |
gptkb:President_of_the_United_States
|
| gptkbp:supports |
research and development
telehealth services patient advocacy groups vaccine development biomedical innovation chronic disease management initiatives digital_health_technologies |
| gptkbp:updates |
user fees for drug manufacturers
|